Myc相关性弥漫大B细胞淋巴瘤的靶向治疗策略研究进展  

Targeted therapeutic strategy for Myc-associated diffuse large B cell lymphomas

作　　者：孔令喆 贾晓辉[1] 王先火[1] 张会来[1] 

机构地区：[1]天津医科大学肿瘤医院国家肿瘤临床医学研究中心天津市"肿瘤防治"重点实验室天津市恶性肿瘤临床医学研究中心,天津300060

出　　处：《肿瘤》2017年第8期895-900,共6页Tumor

摘　　要：Myc作为一个核心的转录因子,可以调控细胞增殖、周期进程、凋亡、分化和代谢等众多功能。而且在弥漫大B细胞淋巴瘤(diuse large B cell lymphoma,DLBCL)中,Myc异常被认为是一个独立预后因素。Myc相关性DLBCL极具侵袭性,对标准化疗方案相对不敏感,预后较其他类型的DLBCL差。通常认为Myc本身无成药性,目前直接抑制Myc的大量药理学研究尚未取得实质性成果。然而,随着对Myc生物学功能的深入了解,人们开发出了一系列靶向Myc转录和蛋白质调节的小分子抑制剂。目前,针对Myc的拮抗策略主要包括干扰其稳定性、减少其表达以及作用其下游靶基因等。本文主要讨论Myc相关性DLBCL靶向治疗的分子机制和研究进展,以期为改善这类患者的预后提供思路。Myc behaves as a central transcriptional factor, regulating cell proliferation, cell cycle progression, apoptosis, differentiation, metabolism and other functions. In diffuse large B cell lymphomas （DLBCL）, Myc abnormality has been identified as an independent prognostic marker. Myc-associated DLBCL tends to have more aggressive phenotypes, lower sensitivity to standard chemotherapeutic regimens, and worse outcomes compared with other types of DLBCL. Myc per se has generally been deemed undruggable, and the pharmacological attempts to directly inhibit Myc have not borne fruits. However, with the understanding of biological functions of Myc, a series of small molecular inhibitors targeting Myc transcription and protein regulation have been developed. The potential antagonistic strategies for Myc mainly include interfering with its stability, decreasing its expression, and acting on the downstream target genes. This review discusses the therapeutic targets for Myc-related DLBCL, with an emphasis on their mechanisms and advances, in the hope to improve the outcomes of these patients.

关 键 词：淋巴瘤 大B细胞 弥漫性 MYC 靶向治疗 

分 类 号：R733.41[医药卫生—肿瘤]